SuperworthDBV Technologies DBVT
- Market cap
- $577.3M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 115×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $5M
- +32% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- n/m
- not a meaningful number
DBV Technologies trades at 115× sales. Its trailing earnings are negative, so it has no PE. Revenue was $5M over the last twelve months, up 32% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.4M+14% | $8.9M | $1.4M−36% | $1.2M−49% | $1.1M−55% | $511K−94% | $753K−47% | $1.5M+26% | $2.8M+159% | $645K+26% | $900K+20% | $700K−52% | |
| R&D | $13.8M−9% | $12.8M | $21.4M+34% | $25.4M+44% | $23.7M+72% | $18.9M+48% | $21.5M+0% | $33.7M+33% | $28.6M+21% | $32.9M+74% | $33.4M+56% | $31.2M−7% |
| SG&A | $6.8M+37% | $8M | $8.6M+17% | $9.6M−1% | $7.7M+13% | $5.5M−32% | $5.9M−31% | $8.9M−8% | $8.4M+9% | $12.8M+134% | $15.3M+160% | $20.1M+126% |
| −$18.3M+1% | −$11.9M | −$28.6M+35% | −$33.8M+35% | −$30.3M+66% | −$23.9M+100% | −$26.6M−7% | −$41.1M+22% | −$34.3M+13% | −$45.1M+89% | −$47.9M+80% | −$50.6M+23% | |
| Pre-tax income | −$16.7M−3% | −$11.2M | −$27.3M+33% | −$33.1M+37% | −$30.4M+82% | −$23M+106% | −$27.1M−1% | −$41.8M+26% | −$33.2M+9% | −$44.5M+93% | −$47.4M+75% | −$50.2M+20% |
| $0 | −$6K | $48K | $0 | $0 | $7K | $0 | $117K | $0 | $374K+5243% | $200K | $200K+71% | |
| Net income | −$16.7M−3% | −$11.2M−72% | −$27.3M+33% | −$33.1M+37% | −$30.4M+82% | −$23M+106% | −$27.1M−1% | −$41.9M+26% | −$33.2M+9% | −$44.8M+95% | −$47.6M+76% | −$50.4M+20% |
| −$1.70−6% | −$1.20−71% | −$2.80+27% | −$1.70−35% | −$1.60−6% | −$0.23−81% | −$0.26−91% | −$0.31−82% | −$0.24−85% | −$0.24+4% | −$0.11−58% | −$0.12−61% | |
| 9.6M+2% | 9.6M+2% | 9.6M+2% | 19.2M+104% | 19.2M+100% | 99.4M+935% | 102.6M+967% | 134.5M+599% | 136.8M+611% | 183.6M+85% | 428.3M+317% | 433.5M+222% |
Income tax: Q1 FY20: 6 months less the 3 months printed beside them.
EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest DBV Technologies' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| DBVTDBV Technologies | $577.3M | n/m | n/a | 115× | +32% | n/m | |
| MGTXMeiraGTx | $884.6M | 13.0× | 18.0× | 2.2× | n/m | 19.9% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| VCELVericel | $2.2B | 92.5× | 158× | 7.1× | +23% | 7.9% | |
| ADMAAdma Biologics | $2.4B | 15.3× | 21.5× | 4.7× | +8% | 33.0% | |
| Peer median | $1.5B | 14.1× | 27.8× | 3.6× | +23% | 21.7% |
Investors who own it
Investors we follow who held DBV Technologies at the end of Jun 30, 2026, from their 13F filings.
- Stanley DruckenmillerDuquesne Family Office0.1% of portfolio
More on DBV Technologies
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .